Drug Trial Radar · NCT06514807
A Study to Evaluate the Efficacy and Safety of Ropeginterferon Alfa-2b in Essential Thrombocythaemia Patients
Last checked: Nov 20, 2026Latest source record: Dec 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
117
Planned (sponsor's estimate)
Start
Dec 4, 2023
Primary completion
Mar 15, 2028
Study completion Mar 15, 2028
Sponsor
- Lead sponsor
- AOP Orphan Pharmaceuticals AGIndustry
- Sponsor type
- Industry
- First posted
- Jul 23, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to assess the efficacy of ropeginterferon alfa-2b in patients with ET who need cytoreductive treatment but are intolerant or refractory to, and/or ineligible for cytoreductive treatments approved and available for the treatment of ET (i.e., HU, ANA, BUS, and PB, when they are available and approved for ET treatment). Ropeginterferon alfa-2b is currently the only interferon authorised as a cytoreductive treatment of a myeloproliferative neoplasm (MPN), and the long-term treatment data from its comprehensive clinical development program show its efficacy in the induction of haematologic remission, resolution of disease-associated symptoms, disease-modifying effect, as well as its favourable safety profile (Gisslinger et al., 2020; Kiladjian et al. 2022). Available clinical data and experience show that ropeginterferon alfa-2b normalises various haematological parameters, including platelets. In addition, suppression of the malignant clone causing ET may be achieved, at least after long-term treatment, which is expected to possibly defer the onset of, or avoid long-term sequelae of ET.
Conditions
- Essential Thrombocythaemia
Interventions
Ropeginterferon alfa-2b (BESREMi®)Drug
Ropeginterferon alfa-2b 250 micrograms/0.5 mL or 500 micrograms/0.5 ml solution for injection in pre-filled pen.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Durable (for at least 3 months) peripheral blood count remissionTime frame: At month 12
- Absence of haemorrhagic or thrombotic events and absence of disease progression*Time frame: At month 12
- Absence or Non-progression* in disease-related signsTime frame: At month 12
- Durable (for at least 3 months) large symptoms improvement or maintenance of non-progression based on the Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPN-SAF TSS)#Time frame: At month 12
Locations
36 sites in 10 countries. Site status is shown where the registry gives one.
Medical University Vienna, Department of Internal Medicine I, Clinical Department of Hematology and Hemostaseology
Vienna, Austria
University Hospital Graz, Department of Internal Medicine, Clinical Department of Hematology
Graz, Styria, Austria
Medical University Innsbruck, Department of Internal Medicine V (Hematology and Oncology)
Innsbruck, Tyrol, Austria
Ordensklinikum Linz GmbH Elisabethinen Hospital, Department of Internal Medicine I - Hemato-Oncology
Linz, Upper Austria, Austria
University Hospital Brno, Clinic of Internal Medicine - Hematology and Oncology
Brno, Czechia
University Hospital Kralovske Vinohrady, Clinic of Internal Hematology
Prague, Czechia
Saint-Louis Hospital, Department of Adult Hematology
Paris, France
Bordeaux University Hospital, Haut-Leveque Hospital
Pessac, France
Centre Hospitalier Universitaire De Poitiers
Poitiers, Poitiers, France
University Hospital Aachen, Clinic of Oncology, Hematology and Stem Cell Transplantation (Medical Clinic IV)
Aachen, Germany
University Hospital Halle (Saale), Department of Internal Medicine IV - Hematology and Oncology
Halle, Germany
Hannover Medical School, Clinic for haematology, haemostaseology, oncology and stem cell transplantation
Hanover, Germany
University Hospital Mannheim, Medical Clinic III, Hematology and Internistic Oncology
Mannheim, Germany
Johannes Wesling Hospital Minden, Department of Oncology and Hematology
Minden, Germany
University Hospital Ulm, Center for Internal Medicine, Clinic of Internal Medicine III, Department of Hematology, Oncology, Rheumatology, Infectious Diseases
Ulm, Germany
General Hospital of Athens Alexandra, Therapeutic Clinic, Department of Therapeutics
Athens, Greece
University General Hospital "Attikon"
Athens, Greece
Semmelweis University, Department of Internal Medicine and Haematology, Division of Hematology
Budapest, Hungary
University of Debrecen Clinical Center, Clinic of Internal Medicine, Department of Hematology
Debrecen, Hungary
Polyclinic S. Orsola-Malpighi
Bologna, Italy
Careggi University Hospital, Department of Hematology
Florence, Italy
Umberto I Polyclinic of Rome
Rome, Italy
University Polyclinic Foundation "Agostino Gemelli" - IRCCS, Service of Hematology
Rome, Italy
University Hospital City of Health and Science of Turin - Hospital Molinette, Complex Structure of Hematology - U
Turin, Italy
University Teaching Centre, Hematology and Transplantology Clinic
Gdansk, Poland
Pratia Oncology Katowice
Katowice, Poland
Independent Public Healthcare Facility University Hospital in Krakow, Teaching Unit of the Hematology Department
Krakow, Poland
Nicolaus Copernicus Provincial Multispecialty Oncology and Traumatology Center in Lodz, Department of Hematooncology with Subdivision of Daytime Chemotherapy
Lodz, Poland
Onco Card Srl
Brasov, Romania
"Prof. Dr. Ion Chiricuta" Institute of Oncology, Hematology Department
Cluj-Napoca, Romania
Fundeni Clinical Institute, Center for Hematology and Bone Marrow Transplantation
Crişan, Romania
Iasi Regional Institute of Oncology, Department of Hematology
Iași, Romania
University Hospital Germans Trias i Pujol
Badalona, Spain
Hospital Clinic of Barcelona, Department of Hematology
Barcelona, Spain
University Hospital Ramon y Cajal, Hematology Service
Madrid, Spain
Morales Meseguer University General Hospital
Murcia, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.